SAB Biotherapeutics, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
SABS Nasdaq 2834 www.sab.bio

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SAB Biotherapeutics, Inc.

SAB BIO to Participate in Upcoming Investor Conferences - Sep 1st, 2026 6:30 am
SAB Biotherapeutics Q2 Earnings Call Highlights - Aug 7th, 2026 6:03 am
SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ... - Aug 6th, 2026 5:14 pm
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - Aug 6th, 2026 5:30 am
SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET - Jul 30th, 2026 6:30 am
SAB Biotherapeutics (SABS) and Breakthrough T1D Award Research Grant For SAB-142 Assessment - Jul 15th, 2026 9:43 am
Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes - Jul 7th, 2026 6:00 am
Why Is H.C. Wainwright Bullish On SAB Biotherapeutics (SABS) With $10 Price Target? - Jul 5th, 2026 4:08 pm
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc. (SABS) - Jun 30th, 2026 10:34 am
SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting - May 29th, 2026 6:00 am
Emergent BioSolutions Inc. (EBS) Gains Attention as ACAM2000 Receives Broader Public Health Authorization - May 20th, 2026 2:43 pm
We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully - May 15th, 2026 5:32 am
SAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ... - May 12th, 2026 5:03 pm
SAB Biotherapeutics Q1 Earnings Call Highlights - May 12th, 2026 11:14 am
SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights - May 12th, 2026 5:30 am
SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET - May 5th, 2026 6:30 am
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 - Apr 29th, 2026 5:35 am
SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 - Apr 22nd, 2026 5:00 am
SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress - Apr 15th, 2026 6:00 am